A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation.
about
A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumoursPemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neckPhase 2 trial of pemetrexed in children and adolescents with refractory solid tumors: a Children's Oncology Group study.Phase II study of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer.Efficacies and adverse reactions of modified vitamin supplement programs before pemetrexed chemotherapy as a second-line treatment against epidermal growth factor receptor (EGFR) mutant wild-type lung adenocarcinoma.In vitro study on the schedule-dependency of the interaction between pemetrexed, gemcitabine and irradiation in non-small cell lung cancer and head and neck cancer cellsPemetrexed in advanced non-small-cell lung cancer.Pemetrexed disodium in ovarian cancer treatment.A prospective study of shortened vitamin supplementation prior to cisplatin-pemetrexed therapy for non-small cell lung cancerThe pemetrexed/gemcitabine combination in pancreatic cancer.Pemetrexed for the treatment of non-small-cell lung cancer.Emerging role of pemetrexed in ovarian cancer.Recent developments in the pharmacological treatment of advanced pancreatic cancer.Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumorsPredicting success in regulatory approval from Phase I results.An evaluation of pemetrexed in second-line treatment of non-small cell lung cancer.Clinical activity of pemetrexed: a multitargeted antifolate anticancer agent.Principles of dose finding studies in cancer: a comparison of trial designs.Impact of renal function on treatment options and outcomes in advanced non-small cell lung cancer.Pharmacokinetic evaluation of pemetrexed.The place of pemetrexed in the management of non-small-cell lung cancer patients.The current state of pemetrexed in ovarian cancer.Chemotherapy in Metastatic NSCLC - New Regimens (Pemetrexed, Nab-Paclitaxel)Effects of pemetrexed, gefitinib, and their combination on human colorectal cancer cells.Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors.Phase II study of oral vitamin B12 supplementation as an alternative to intramuscular injection for patients with non-small cell lung cancer undergoing pemetrexed therapy.Unusually prolonged pemetrexed cytotoxicity in a patient with a lung adenocarcinoma: a case report.Biliary Elimination of Pemetrexed Is Dependent on Mrp2 in Rats: Potential Mechanism of Variable Response in Nonalcoholic Steatohepatitis.Acute Tubular Necrosis and Interstitial Nephritis during Pemetrexed Therapy.2012 Annual Meeting of the Safety Pharmacology Society: spotlight on targeted oncology medicines.Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group.Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients.Cytotoxic effects of pemetrexed in gastric cancer cells.Lansoprazole Exacerbates Pemetrexed-Mediated Hematologic Toxicity by Competitive Inhibition of Renal Basolateral Human Organic Anion Transporter 3.
P2860
Q28200350-59D6BCB5-0575-4027-8EF4-A23858D22CB1Q28347912-7F6800C4-491E-4AA0-A663-1ED0A9E7FD1BQ33402047-DDC2C959-923F-487D-8B01-EC7A2482FC80Q33410746-9B9FB4D1-F170-49EC-B252-8F2661E77C94Q33427414-BD7333B0-A4A6-4368-B5E1-4F9E8744E879Q33665367-DC141B1B-104C-4636-8304-BD38F220C81CQ34113895-A008D98E-39E0-4394-B61A-B877A9FA8C20Q34253505-2F557E6A-A071-4864-8238-420AE9332257Q34458042-B97DDF5D-6ED2-4986-A858-3CD026E58C8DQ34810763-A4CE1159-9064-4392-A932-9BBB95B0F856Q35003631-5F37A677-EDE5-45B3-B358-9EF67AFE4008Q35015611-3D5B4335-3B63-4B4E-BF7F-C37F79892456Q35144004-5F9E2BAF-AAA3-4A9D-B2E6-1757A96D657BQ35751860-9C0E1269-17FA-49C5-A1A9-6C81D79E8F44Q35809924-F7028F2A-40D7-4CD1-A6BB-0721BB9258BBQ36327104-F7FEBECE-A385-4520-A4AC-8A9631DB93BFQ36429607-11B8398E-7737-4B97-8647-41168CEE60FAQ36795347-F72597C7-FEC6-4DA5-8BB7-558F056A7851Q36823770-A4191395-58D6-43FE-9370-936CBD3E3561Q37877715-7890E511-2C46-4EA1-B82E-A33ED8756947Q38087999-D19C83D7-5822-4B65-8C4F-BC5257C06E80Q38125259-91BCEC54-076E-46F5-A881-7F6C358E7A02Q38237655-05396FB1-B86D-44F7-8EA0-5002C26233A3Q39108067-F951A4D6-11B1-412B-927E-739E7F4CFCE3Q40345312-915B99C4-2766-4BDB-BB7F-7FE8FD3B9071Q40814215-CB5D8C6F-5278-4220-A455-260CE351E0BEQ41714739-9243FA34-F95B-494B-8851-484A53692995Q41814330-868112D0-4CD6-4FCB-8BF0-EFA7F2317DECQ42553403-8CB4D6DD-BBE9-4483-BF6C-71D3F5D34895Q42598966-D1448EE1-57E0-4E62-A77D-DC6EF317A863Q43707358-0D4F67A9-B4CF-4A94-A8BC-F0662310E2ACQ44965471-F8977DDE-946B-4974-9FF1-08D7D72E9FC9Q46548607-92675590-91FC-41E6-B3B2-B2BFCEEF3413Q53052634-86289F74-3841-4E90-8C10-18AEA85F3E27
P2860
A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation.
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
A phase I evaluation of multit ...... nt method for dose escalation.
@ast
A phase I evaluation of multit ...... nt method for dose escalation.
@en
A phase I evaluation of multit ...... nt method for dose escalation.
@nl
type
label
A phase I evaluation of multit ...... nt method for dose escalation.
@ast
A phase I evaluation of multit ...... nt method for dose escalation.
@en
A phase I evaluation of multit ...... nt method for dose escalation.
@nl
prefLabel
A phase I evaluation of multit ...... nt method for dose escalation.
@ast
A phase I evaluation of multit ...... nt method for dose escalation.
@en
A phase I evaluation of multit ...... nt method for dose escalation.
@nl
P2093
P356
P1476
A phase I evaluation of multit ...... ent method for dose escalation
@en
P2093
Abrahams T
Eckhardt SG
Mascorro D
Rinaldi DA
Rodriguez G
P2888
P304
P356
10.1007/S002800050992
P577
1999-01-01T00:00:00Z
P6179
1039955144